Recce Pharmaceuticals Ltd has unveiled that the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, Copolymer and Method for Treatment of Bacterial Infection'.
The USA represents close to half of the world's USD $42.33 billion antibiotic market by value(1). This patent is Recce's second wholly owned patent to be Granted in USA and secures significant and additional monopolies for Recce to November 2035.
The Granted patent contains a suite of 23 claims including its lead candidate RECCE[R] 327.
Recce's commercialization strategy is focused on leveraging its expanding local and international intellectual property estate.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs....